Lantern Pharma Inc
LTRN3.550USD
-0.080-2.20%
Fechamento 11/05, 16:00（ET）Cotações atrasadas em 15 min
38.29MValor de mercado
PerdaP/L TTM
Mais detalhes de Lantern Pharma Inc Empresa
Lantern Pharma Inc. is an artificial intelligence (AI) company. The Company is developing targeted and transformative cancer therapies using its proprietary RADR AI and machine learning (ML) platform with multiple clinical-stage drug programs. Its proprietary AI and machine learning (ML) platform, RADR, leverages over 60 billion oncology-focused data points and a library of over 200 advanced ML algorithms to help solve problems in oncology drug development. It is engaged in the development of its pipeline of therapies that span multiple cancer indications, including both solid tumors and blood cancers and an antibody drug conjugate (ADC) program. It has active clinical programs for its three lead small molecule drug candidates: LP-300, LP-184, and LP-284. These programs are focused on multiple cancer indications, including both solid tumors and blood cancers. It is also focused on the clinical execution of its therapies for CNS and brain cancers through Starlight Therapeutics Inc.
Informações de Lantern Pharma Inc
Código da empresaLTRN
Nome da EmpresaLantern Pharma Inc
Data de listagemJun 11, 2020
CEOMr. Panna L. Sharma
Número de funcionários24
Tipo de títulosOrdinary Share
Fim do ano fiscalJun 11
Endereço1920 Mckinney Avenue
CidadeDALLAS
Bolsa de valoresNASDAQ Capital Market Consolidated
PaísUnited States of America
Código postal75201
Telefone19722771136
Sitehttps://www.lanternpharma.com/
Código da empresaLTRN
Data de listagemJun 11, 2020
CEOMr. Panna L. Sharma
Executivos da empresa Lantern Pharma Inc
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Maria L. Maccecchini, Ph.D.
Dr. Maria L. Maccecchini, Ph.D.
Independent Director
Independent Director
--
--
Dr. David S. Silberstein, Ph.D.
Dr. David S. Silberstein, Ph.D.
Independent Director
Independent Director
--
--
Dr. Donald Jeff Keyser, J.D., Ph.D.
Dr. Donald Jeff Keyser, J.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Panna L. Sharma
Mr. Panna L. Sharma
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. David R. Margrave, J.D.
Mr. David R. Margrave, J.D.
Chief Financial Officer, Secretary
Chief Financial Officer, Secretary
--
--
Dr. Kishor G. Bhatia, Ph.D.
Dr. Kishor G. Bhatia, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Dr. Vijay Chandru, Ph.D.
Dr. Vijay Chandru, Ph.D.
Independent Director
Independent Director
--
--
Dr. Lee T. Schalop, M.D.
Dr. Lee T. Schalop, M.D.
Director
Director
--
--
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Maria L. Maccecchini, Ph.D.
Dr. Maria L. Maccecchini, Ph.D.
Independent Director
Independent Director
--
--
Dr. David S. Silberstein, Ph.D.
Dr. David S. Silberstein, Ph.D.
Independent Director
Independent Director
--
--
Dr. Donald Jeff Keyser, J.D., Ph.D.
Dr. Donald Jeff Keyser, J.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Panna L. Sharma
Mr. Panna L. Sharma
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. David R. Margrave, J.D.
Mr. David R. Margrave, J.D.
Chief Financial Officer, Secretary
Chief Financial Officer, Secretary
--
--
Dr. Kishor G. Bhatia, Ph.D.
Dr. Kishor G. Bhatia, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Detalhamento da receita
Sem dados
Sem dados
Por Empresa
Por Região
Sem dados
Distribuição de ações
Atualizado em: qui, 7 de ago
Atualizado em: qui, 7 de ago
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
Bios Equity Partners, LP.
9.96%
Biological Mimetics, Inc
7.82%
Prophase Labs Inc
5.84%
The Vanguard Group, Inc.
3.37%
CM Management, LLC
1.85%
Outro
71.16%
Investidores
Investidores
Proporção
Bios Equity Partners, LP.
9.96%
Biological Mimetics, Inc
7.82%
Prophase Labs Inc
5.84%
The Vanguard Group, Inc.
3.37%
CM Management, LLC
1.85%
Outro
71.16%
Tipos de investidores
Investidores
Proporção
Corporation
13.66%
Venture Capital
10.08%
Investment Advisor
7.31%
Investment Advisor/Hedge Fund
2.15%
Hedge Fund
1.31%
Individual Investor
0.42%
Research Firm
0.12%
Outro
64.95%
Participação acionária institucional
Atualizado em: qua, 1 de out
Atualizado em: qua, 1 de out
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q3
75
2.26M
20.96%
-504.83K
2025Q2
71
3.78M
35.06%
-589.53K
2025Q1
73
4.04M
37.50%
-292.34K
2024Q4
75
4.10M
38.06%
-404.66K
2024Q3
73
4.20M
39.03%
-539.55K
2024Q2
74
4.17M
38.76%
-357.16K
2024Q1
68
4.00M
36.90%
-906.94K
2023Q4
66
4.18M
38.50%
-1.07M
2023Q3
73
4.62M
42.50%
-2.30M
2023Q2
72
4.61M
42.49%
-2.27M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
Bios Equity Partners, LP.
1.08M
9.96%
-157.85K
-12.79%
Jun 30, 2025
Biological Mimetics, Inc
844.13K
7.82%
--
--
Jul 23, 2025
Prophase Labs Inc
631.20K
5.84%
--
--
Jul 23, 2025
The Vanguard Group, Inc.
363.72K
3.37%
--
--
Jun 30, 2025
CM Management, LLC
200.00K
1.85%
--
--
Jun 30, 2025
Geode Capital Management, L.L.C.
91.89K
0.85%
+1.39K
+1.53%
Jun 30, 2025
Renaissance Technologies LLC
90.60K
0.84%
+1.80K
+2.03%
Jun 30, 2025
GWM Advisors LLC
56.51K
0.52%
-3.42K
-5.70%
Jun 30, 2025
Voss Capital LLC
50.00K
0.46%
--
--
Jun 30, 2025
Keyser (Donald Jeffrey PH.D)
45.76K
0.42%
--
--
Jul 23, 2025
Ver Mais
ETFs Relacionados
Atualizado em: há 18 minutos
Atualizado em: há 18 minutos
Nome
Proporção
iShares Micro-Cap ETF
0.01%
Avantis US Small Cap Equity ETF
0%
DFA Dimensional US Sustainability Core 1 ETF
0%
Dimensional US Core Equity 1 ETF
0%
iShares Micro-Cap ETF
Proporção0.01%
Avantis US Small Cap Equity ETF
Proporção0%
DFA Dimensional US Sustainability Core 1 ETF
Proporção0%
Dimensional US Core Equity 1 ETF
Proporção0%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Sem dados
Data
Tipo
Proporção
Sem dados
